focus -WSS

focus

author：hotspot 2025-09-06 03:53:56 - browse：7166

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Readout LOUD podcast: live from JPM 2024

focus

WSS

Heart disease and mental health: A look at cardiac psychology

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Novel spinal cord stimulator treats paralysis without surgery

Is it ever OK for doctors to lie to their patients?

Chemotherapy before breast cancer surgery might fuel metastasis

Crowdfunding for medical bills sidesteps core problem, author says

hotspot

focus

focus

Sports medicine is finally prioritizing gender equality

Novel spinal cord stimulator treats paralysis without surgery

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The creative science of coining drug names

Cancer drug shortages should be causing more outrage

BIO to announce reorganization, senior leaders expected to depart

Virginia high school admissions case could be legal follow

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

focus

Risky weight loss products often used by teens globally, per study

Doulas covered by Medicaid under New York's new plan

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Warren pushes Witty on UnitedHealth's control over physicians

Empower primary care with adequate payments and technology

Doulas covered by Medicaid under New York's new plan

Wikipedia

focus

leisure time

hotspot